ArticlePLoS neglected tropical diseases2026
Trichinella spiralis galectin disrupts gut epithelial integrity and mediates larval invasion via acting MUC13- ROCK2/MAPK pathway.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGut epithelium serves as a critical barrier against Trichinella spiralis larval invasion, parasite-derived galectins are involved in host-parasite interactions, including invasion and immune modulation. This study investigated the role of T. spiralis galectin (Tsgal) in gut epithelial barrier disruption and larval invasion. METHODOLOGY/PRINCIPAL
findingsRecombinant Tsgal (rTsgal) was expressed in vitro and its interaction with intestinal epithelial cells (IEC) was ascertained using immunofluorescence test (IFT) and confocal microscopy. The rTsgal-specific binding IEC proteins were identified by GST pull-down, mass spectrometry (MS) and Co-immunoprecipitation (Co-IP) assay. Intestinal epithelial integrity damage induced by rTsgal was evaluated by IFT, qPCR and Western blotting analysis. The in vitro larva invasive assay was also conducted. The results showed that rTsgal bound and interacted specifically with MUC13 receptor in Caco-2 cells. rTsgal activated MUC13-ROCK2/MAPK pathway, reduced the expression of gut epithelial tight junctions (TJs; ZO-1, E-cad, Occludin and Claudin-1), increased gut epithelial permeability, disrupted gut epithelial integrity and barrier functions, thereby facilitated larva invasion of Caco-2 monolayers. Moreover, MUC13 receptor inhibitor (Cuc D), MUC13 knockdown of Caco-2 cells, ROCK2 inhibitor (KD025) and p38-MAPK inhibitor (SB203580) suppressed this pathway activation, restored gut epithelial integrity, and impeded larval invasion.
conclusionsTsgal disrupted gut epithelial integrity and mediated larval invasion through binding to MUC13 receptor and activating ROCK2/MAPK pathway. Tsgal might be a potential target molecule for development of novel drugs and vaccines to block T. spiralis infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.